A multicenter, primary-care-based, open-label study to assess the success of converting opioid-experienced patients with chronic moderate-to-severe pain to morphine sulfate and naltrexone hydrochloride extended-release capsules using a standardized conversion guide

References

• RosenblumAMarschLAJosephHPortenoyRKOpioids and the treatment of chronic pain: controversies, current status, and future directionsExp Clin Psychopharmacol200816540541618837637
   PubMed Web of Science ®Google Scholar
• FieldsHLThe doctor’s dilemma: opiate analgesics and chronic painNeuron201169459159421338871
   PubMed Web of Science ®Google Scholar
• QuigleyCOpioid switching to improve pain relief and drug tolerabilityCochrane Database Syst Rev20043CD00484715266542
   PubMedGoogle Scholar
• Caudill-SlosbergMASchwartzLMWoloshinSOffice visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000Pain2004109351451915157714
   PubMed Web of Science ®Google Scholar
• TrescotAMHelmSHansenHOpioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians (ASIPP) GuidelinesPain Physician2008112 SupplS5S6218443640
   PubMed Web of Science ®Google Scholar
• WarnerEAOpioids for the treatment of chronic noncancer painAm J Med2012125121155116122944349
   PubMed Web of Science ®Google Scholar
• NobleMTregearSJTreadwellJRSchoellesKLong-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safetyJ Pain Symptom Manage200835221422818178367
   PubMed Web of Science ®Google Scholar
• SlatkinNEOpioid switching and rotation in primary care: implementation and clinical utilityCurr Med Res Opin20092592133215019601703
   PubMed Web of Science ®Google Scholar
• KnotkovaHFinePGPortenoyRKOpioid rotation: the science and the limitations of the equianalgesic dose tableJ Pain Symptom Manage200938342643919735903
   PubMed Web of Science ®Google Scholar
• ChouRFanciulloGJFinePGAmerican Pain Society-American Academy of Pain Medicine Opioids Guidelines PanelClinical guidelines for the use of chronic opioid therapy in chronic noncancer painJ Pain20091021330
   Web of Science ®Google Scholar
• NalamachuSROpioid rotation in clinical practiceAdv Ther2012291084986323054690
   PubMed Web of Science ®Google Scholar
• WebsterLRBrewerRMorrisDClevelandJMSetnikBOpioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsulesPostgrad Med2011123515516421904098
   PubMed Web of Science ®Google Scholar
• FinePGPortenoyRKEstablishing “best practices” for opioid rotation: conclusions of an expert panelJ Pain Symptom Manage200938341842519735902
   PubMed Web of Science ®Google Scholar
• VissersKCBesseKHansGDevulderJMorlionBOpioid rotation in the management of chronic pain: where is the evidence?Pain Pract2010102859320070552
   PubMed Web of Science ®Google Scholar
• AndersonRSaiersJHAbramSSchlichtCAccuracy in equianalgesic dosing. Conversion dilemmasJ Pain Symptom Manage200121539740611369161
   PubMed Web of Science ®Google Scholar
• PereiraJLawlorPViganoADorganMBrueraEEquianalgesic dose ratios for opioids. A critical review and proposals for long-term dosingJ Pain Symptom Manage200122267268711495714
   PubMed Web of Science ®Google Scholar
• ShaheenPEWalshDLasheenWDavisMPLagmanRLOpioid equianalgesic tables: are they all equally dangerous?J Pain Symptom Manage200938340941719735901
   PubMed Web of Science ®Google Scholar
• KatzNHaleMMorrisDStaufferJMorphine sulfate and naltrex-one hydrochloride extended release capsules in patients with chronic osteoarthritis painPostgrad Med2010122411212820675975
   PubMed Web of Science ®Google Scholar
• KatzNSunSJohnsonFStaufferJALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safetyJ Pain201011430331119944650
   PubMed Web of Science ®Google Scholar
• WebsterLRBrewerRWangCLong-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe painJ Pain Symptom Manage201040573474621075272
   PubMed Web of Science ®Google Scholar
• EMBEDA® (morphine sulfate and naltrexone hydrochloride) [package insert]Bristol, TNPfizer Inc2009
   Google Scholar
• American Pain SocietyPrinciples of Analgesic Use in the Treatment of Acute Pain and Cancer Pain5th edGlenview, ILAmerican Pain Society2003
   Google Scholar
• GordonDBStevensonKKGriffieJMuchkaSRappCFord-RobertsKOpioid equianalgesic calculationsJ Palliat Med19992220921815859817
   PubMedGoogle Scholar
• SloanPSlatkinNAhdiehHEffectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot studySupport Care Cancer2005131576515538638
   PubMed Web of Science ®Google Scholar
• LevyMHPharmacologic treatment of cancer painN Engl J Med199633515112411328813044
   PubMed Web of Science ®Google Scholar
• CleelandCSRyanKMPain assessment: global use of the Brief Pain InventoryAnn Acad Med Singapore19942321291388080219
   PubMedGoogle Scholar
• WeschulesDJBainKTA systematic review of opioid conversion ratios used with methadone for the treatment of painPain Med20089559561218565004
   PubMed Web of Science ®Google Scholar
• MorylNSantiago-PalmaJKornickCPitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer painPain200296332532811973005
   PubMed Web of Science ®Google Scholar
• LawlorPGTurnerKSHansonJBrueraEDDose ratio between morphine and methadone in patients with cancer pain: a retrospective studyCancer1998826116711739506365
   PubMed Web of Science ®Google Scholar
• AshbyMAMartinPJacksonKAOpioid substitution to reduce adverse effects in cancer pain managementMed J Aust19991702687110026686
   PubMed Web of Science ®Google Scholar
• de StoutzNDBrueraESuarez-AlmazorMOpioid rotation for toxicity reduction in terminal cancer patientsJ Pain Symptom Manage19951053783847673770
   PubMed Web of Science ®Google Scholar
• MaddocksISomogyiAAbbottFHayballPParkerDAttenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodoneJ Pain Symptom Manage19961231821898803381
   PubMed Web of Science ®Google Scholar
• MercadanteSFerreraPVillariPCasuccioAIntravaiaGMangioneSFrequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unitJ Pain Symptom Manage200937463264119345298
   PubMed Web of Science ®Google Scholar
• GriloRMBertinPScotto di FazanoCOpioid rotation in the treatment of joint pain. A review of 67 casesJoint Bone Spine200269549149412477234
   PubMed Web of Science ®Google Scholar
• Quang-CantagrelNDWallaceMSMagnusonSKOpioid substitution to improve the effectiveness of chronic noncancer pain control: a chart reviewAnesth Analg200090493393710735802
   PubMed Web of Science ®Google Scholar
• RolandCLSetnikBClevelandJMBrownDAClinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodonePostgrad Med2011123414815921680999
   PubMed Web of Science ®Google Scholar
• FarrarJTYoungJPJrLaMoreauxLWerthJLPooleRMClinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain200194214915811690728
   PubMed Web of Science ®Google Scholar
• BrownJSetnikBLeeKEffectiveness and safety of morphine sulfate extended-release capsules in patients with chronic, moderate-to-severe pain in a primary care settingJ Pain Res2011437338422090806
   PubMedGoogle Scholar
• McCarbergBHBillingtonRConsequences of neuropathic pain: quality-of-life issues and associated costsAm J Manag Care2006129 SupplS263S26816774458
   PubMed Web of Science ®Google Scholar
• BadalamentiVCBuckleyJWSmithETSafety of EMBEDA (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first yearJ Opioid Manag20128211512522616317
   PubMedGoogle Scholar
• SetnikBGoliVLevy-CoopermanNMillsCShramMSmithIAssessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid usersPain Res Manag2013184e55e6223936895
   PubMed Web of Science ®Google Scholar
• SetnikBSommervilleKGoliVHanLWebsterLRAssessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid usersPain Med20131481173118623745947
   PubMed Web of Science ®Google Scholar
• StaufferJSetnikBSokolowskaMRomachMJohnsonFSellersESubjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover studyClin Drug Investig20092912777790
   PubMed Web of Science ®Google Scholar
• WebsterLRJohnsonFKStaufferJSetnikBCiricSImpact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid usersDrugs R D201111325927521902287
   PubMedGoogle Scholar
• JangDHRoheJCHoffmanRSNelsonLSSevere opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda)Ann Emerg Med201055330330420171465
   PubMed Web of Science ®Google Scholar
• RuanXChenTGudinJCouchJPChiravuriSAcute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literatureJ Opioid Manag20106430030320862910
   PubMedGoogle Scholar